BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castellana M, Donghia R, Guerra V, Procino F, Lampignano L, Castellana F, Zupo R, Sardone R, De Pergola G, Romanelli F, Trimboli P, Giannelli G. Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. J Clin Med 2021;10:1877. [PMID: 33925992 DOI: 10.3390/jcm10091877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang C, Yang M. Current Options and Future Directions for NAFLD and NASH Treatment. Int J Mol Sci 2021;22:7571. [PMID: 34299189 DOI: 10.3390/ijms22147571] [Reference Citation Analysis]
2 George ES, Georgousopoulou EN, Mellor DD, Chrysohoou C, Pitsavos C, Panagiotakos DB. Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012). Nutrients 2022;14:2367. [PMID: 35745097 DOI: 10.3390/nu14122367] [Reference Citation Analysis]
3 Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring) 2021;29:1950-60. [PMID: 34553836 DOI: 10.1002/oby.23263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Han AL, Lee HK. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites 2022;12:664. [DOI: 10.3390/metabo12070664] [Reference Citation Analysis]